EU Rejects Acadia's Rett Syndrome Drug; Company to Seek Re-examination

The European Union's Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on Acadia Pharmaceuticals' drug, trofinetide, intended for the treatment of Rett syndrome. This regulatory setback delays the potential market entry of the drug within the European Union, impacting the company's international growth strategy. The rejection comes despite the positive data previously reported from the pivotal Phase 3 LAVENDER clinical study. In response to the decision, Acadia Pharmaceuticals announced its intention to formally request a re-examination of the committee's opinion. The company remains committed to bringing the treatment to patients and will work to address the specific concerns raised by European regulators. Investors are closely monitoring the situation, as regulatory hurdles in major markets typically increase operational uncertainty and delay revenue streams for biotech firms.